<H1>Chapter DOI: 10.1186/s12950-016-0128-1<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>46</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>42</td></tr><tr><td>BibStructured Count</td><td width="10%">44</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>41</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>3</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>2</td></tr><tr><td>Valid DOI Enriched</td><td>3</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655&#8211;65.</td><td><a href=http://dx.doi.org/10.1056/NEJMra035488>10.1056/NEJMra035488</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>D&#8217;Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343&#8211;9.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-115-5-343>10.7326/0003-4819-115-5-343</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132:373&#8211;9.</td><td><a href=http://dx.doi.org/10.1378/chest.06-2913>10.1378/chest.06-2913</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982&#8211;2006. Eur Respir J. 2007;30:1103&#8211;10.</td><td><a href=http://dx.doi.org/10.1183/09031936.00042107>10.1183/09031936.00042107</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol. 2011;57:1053&#8211;61.</td><td><a href=http://dx.doi.org/10.1016/j.jacc.2010.11.020>10.1016/j.jacc.2010.11.020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011;139:1285&#8211;93.</td><td><a href=http://dx.doi.org/10.1378/chest.10-1293>10.1378/chest.10-1293</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719&#8211;25.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(98)02111-4>10.1016/S0140-6736(98)02111-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S, Bonnet S. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ. 2013;3:278&#8211;93.</td><td><a href=http://dx.doi.org/10.4103/2045-8932.114752>10.4103/2045-8932.114752</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54:S10&#8211;19.</td><td><a href=http://dx.doi.org/10.1016/j.jacc.2009.04.006>10.1016/j.jacc.2009.04.006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Crosswhite P, Sun Z. Molecular mechanisms of pulmonary arterial remodeling. Mol Med. 2014;20:191&#8211;201.</td><td><a href=http://dx.doi.org/10.2119/molmed.2013.00165>10.2119/molmed.2013.00165</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227&#8211;37.</td><td><a href=http://dx.doi.org/10.1016/j.cardiores.2003.11.026>10.1016/j.cardiores.2003.11.026</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol. 2007;5:45&#8211;52.</td><td><a href=http://dx.doi.org/10.2174/157016107779317161>10.2174/157016107779317161</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014;2014:62&#8211;78.</td><td><a href=http://dx.doi.org/10.5339/gcsp.2014.29>10.5339/gcsp.2014.29</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Bressollette E, Dupuis J, Bonan R, Doucet S, Cernacek P, Tardif JC. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest. 2001;120:809&#8211;15.</td><td><a href=http://dx.doi.org/10.1378/chest.120.3.809>10.1378/chest.120.3.809</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Budd DC, Holmes AM. Targeting TGFbeta superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther. 2012;135:279&#8211;91.</td><td><a href=http://dx.doi.org/10.1016/j.pharmthera.2012.06.001>10.1016/j.pharmthera.2012.06.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Lambers C, Roth M, Zhong J, Campregher C, Binder P, Burian B, Petkov V, Block LH. The interaction of endothelin-1 and TGF-beta1 mediates vascular cell remodeling. PLoS One. 2013;8:e73399.</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0073399>10.1371/journal.pone.0073399</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Singh I, Ma KC, Berlin DA. Pathophysiology of pulmonary hypertension in chronic parenchymal lung disease. Am J Med. 2016;129:366&#8211;71.</td><td><a href=http://dx.doi.org/10.1016/j.amjmed.2015.11.026>10.1016/j.amjmed.2015.11.026</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62:D109&#8211;116.</td><td><a href=http://dx.doi.org/10.1016/j.jacc.2013.10.036>10.1016/j.jacc.2013.10.036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Weijun T, Zhenshun C, Qiuyue T, Ting W, Min L, Li Z. Transforming growth factor-beta1 induces epithelial-mesenchymal transition in A549 cells by up-regulating expression of calpain. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38:202&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH, Kim CH, Park YB, Lee MG, Hyun IG, et al. Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells. J Korean Med Sci. 2007;22:898&#8211;904.</td><td><a href=http://dx.doi.org/10.3346/jkms.2007.22.5.898>10.3346/jkms.2007.22.5.898</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56.</td><td><a href=http://dx.doi.org/10.1186/1465-9921-6-56>10.1186/1465-9921-6-56</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Ramos C, Becerril C, Montano M, Garcia-De-Alba C, Ramirez R, Checa M, Pardo A, Selman M. FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010;299:L222&#8211;231.</td><td><a href=http://dx.doi.org/10.1152/ajplung.00070.2010>10.1152/ajplung.00070.2010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Luo YH, Ouyang PB, Tian J, Guo XJ, Duan XC. Rosiglitazone inhibits TGF-beta 1 induced activation of human Tenon fibroblasts via p38 signal pathway. PLoS One. 2014;9:e105796.</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0105796>10.1371/journal.pone.0105796</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res. 2010;11:21.</td><td><a href=http://dx.doi.org/10.1186/1465-9921-11-21>10.1186/1465-9921-11-21</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289&#8211;312.</td><td><a href=http://dx.doi.org/10.1146/annurev.biochem.77.061307.091829>10.1146/annurev.biochem.77.061307.091829</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal. 2009;11:1415&#8211;52.</td><td><a href=http://dx.doi.org/10.1089/ars.2008.2280>10.1089/ars.2008.2280</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Martin-Nizard F, Furman C, Delerive P, Kandoussi A, Fruchart JC, Staels B, Duriez P. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol. 2002;40:822&#8211;31.</td><td><a href=http://dx.doi.org/10.1097/00005344-200212000-00003>10.1097/00005344-200212000-00003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Kim EK, Lee JH, Oh YM, Lee YS, Lee SD. Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respirology. 2010;15:659&#8211;68.</td><td><a href=http://dx.doi.org/10.1111/j.1440-1843.2010.01756.x>10.1111/j.1440-1843.2010.01756.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Kang BY, Kleinhenz JM, Murphy TC, Hart CM. The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2011;301:L881&#8211;891.</td><td><a href=http://dx.doi.org/10.1152/ajplung.00195.2011>10.1152/ajplung.00195.2011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101&#8211;8.</td><td><a href=http://dx.doi.org/10.1038/nprot.2008.73>10.1038/nprot.2008.73</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Talati M, West J, Blackwell TR, Loyd JE, Meyrick B. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;299:L363&#8211;373.</td><td><a href=http://dx.doi.org/10.1152/ajplung.00295.2009>10.1152/ajplung.00295.2009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>West J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:265&#8211;78.</td><td><a href=http://dx.doi.org/10.1007/978-1-60761-500-2_17>10.1007/978-1-60761-500-2_17</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ferreira Rde</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Montenegro</span> <span style='background:#DDDDDD'>SM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Domingues</span> <span style='background:#DDDDDD'>AL</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bandeira</span> <span style='background:#DDDDDD'>AP</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Silveira</span> <span style='background:#DDDDDD'>CA</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Leite</span> <span style='background:#DDDDDD'>LA</span></span>, et al.</aug> <span style='background:#CCCCFF'>TGF beta and IL13 in schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups</span>. <span style='background:#CCFF99'>BMC Infect Dis</span>. <span style='background:#66FF66'>2014</span>;<span style='background:#FFCC66'>14</span>:<span style='background:#D279FF'>282</span>.</td><td><a href=http://dx.doi.org/10.1186/1471-2334-14-282>10.1186/1471-2334-14-282</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Year, Author_FamilyName_2, VolumeID, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009;41:484&#8211;93.</td><td><a href=http://dx.doi.org/10.1165/rcmb.2008-0447OC>10.1165/rcmb.2008-0447OC</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Jonitz A, Fitzner B, Jaster R. Molecular determinants of the profibrogenic effects of endothelin-1 in pancreatic stellate cells. World J Gastroenterol. 2009;15:4143&#8211;9.</td><td><a href=http://dx.doi.org/10.3748/wjg.15.4143>10.3748/wjg.15.4143</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Castanares C, Redondo-Horcajo M, Magan-Marchal N, ten Dijke P, Lamas S, Rodriguez-Pascual F. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci. 2007;120:1256&#8211;66.</td><td><a href=http://dx.doi.org/10.1242/jcs.03419>10.1242/jcs.03419</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Liu Y, Tian XY, Huang Y, Wang N. Rosiglitazone attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the Rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors. PPAR Res. 2014;2014:374075.</td><td><a href=http://dx.doi.org/10.1155/2014/374075>10.1155/2014/374075</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul Pharmacol. 2009;50:45&#8211;50.</td><td><a href=http://dx.doi.org/10.1016/j.vph.2008.09.001>10.1016/j.vph.2008.09.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Tong XK, Hamel E. Transforming growth factor-1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase. Mol Pharmacol. 2009;72:1476&#8211;83.</td><td><a href=http://dx.doi.org/10.1124/mol.107.039602>10.1124/mol.107.039602</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed). 2009;1:226&#8211;35.</td><td><a href=http://dx.doi.org/10.2741/s22>10.2741/s22</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Tian J, Wong WT, Tian XY, Zhang P, Huang Y, Wang N. Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension. 2010;56:129&#8211;35.</td><td><a href=http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.150375>10.1161/HYPERTENSIONAHA.110.150375</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45&#8211;51.</td><td><a href=http://dx.doi.org/10.1161/01.ATV.0000047447.67827.CD>10.1161/01.ATV.0000047447.67827.CD</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Montezano AC, Amiri F, Tostes RC, Touyz RM, Schiffrin EL. Inhibitory effects of PPAR-gamma on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats. J Am Soc Hypertens. 2007;1:150&#8211;60.</td><td><a href=http://dx.doi.org/10.1016/j.jash.2007.01.005>10.1016/j.jash.2007.01.005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Lin CF, Young KC, Bai CH, Yu BC, Ma CT, Chien YC, Chiang CL, Liao CS, Lai HW, Tsao CW. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Biomed Res Int. 2014;2014:787924.</td><td><a href=http://dx.doi.org/10.1155/2014/787924>10.1155/2014/787924</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Matsumoto T, Kobayashi T, Kamata K. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res. 2008;44:41&#8211;55.</td><td><a href=http://dx.doi.org/10.1540/jsmr.44.41>10.1540/jsmr.44.41</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bum-Yong</span> <span style='background:#DDDDDD'>K</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Park</span> <span style='background:#DDDDDD'>KK</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Green</span> <span style='background:#DDDDDD'>DE</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bijli</span> <span style='background:#DDDDDD'>KM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Searles</span> <span style='background:#DDDDDD'>CD</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sutliff</span> <span style='background:#DDDDDD'>RL</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Michael</span> <span style='background:#DDDDDD'>H.</span></span></aug> <span style='background:#CCCCFF'>Hypoxia mediates mutual repression between microRNA-27a and PPAR&#947; in the pulmonary vasculature</span>. <span style='background:#CCFF99'>Plos One</span>. <span style='background:#66FF66'>2013</span>;<span style='background:#FFCC66'>8</span>:<span style='background:#D279FF'>e79503</span>.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0079503>10.1371/journal.pone.0079503</a></td><td><b>CrossRef-Web</b></td>
<td>VolumeID, Author_FamilyName_2, Year, JournalTitle</td><td>CrossRef</td></tr></table>